Lilotomab
Murine monoclonal antibody against CD37
From Wikipedia, the free encyclopedia
Lilotomab (formerly tetulomab, HH1)[1] is a murine monoclonal antibody against CD37,[2] a glycoprotein which is expressed on the surface of mature human B cells.[3] It was generated at the Norwegian Radium Hospital.[3]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | CD37 |
| Clinical data | |
| Other names | Tetulomab, HH1 |
| ATC code |
|
| Identifiers | |
| CAS Number |
|
| ChemSpider |
|
| UNII | |
| KEGG | |
As of 2016 it was under development by the Norwegian company Nordic Nanovector ASA as a radioimmunotherapeutic in which lilotomab is conjugated to the beta radiation-emitting isotope lutetium-177 by means of a linker called satetraxetan, a derivative of DOTA.[2] This compound is called 177Lu-HH1 or lutetium (177Lu) lilotomab satetraxetan (trade name Betalutin).[1] As of 2016, a phase 1/2 clinical trial in people with non-Hodgkin lymphoma was underway.[4]
